AR086880A1 - Derivados de morfolin-benzamidas sustituidas, composiciones farmaceuticas que los contienen y uso de las mismas para tratar enfermedades asociadas fundamentalmente al sistema nervioso central - Google Patents
Derivados de morfolin-benzamidas sustituidas, composiciones farmaceuticas que los contienen y uso de las mismas para tratar enfermedades asociadas fundamentalmente al sistema nervioso centralInfo
- Publication number
- AR086880A1 AR086880A1 ARP120102045A ARP120102045A AR086880A1 AR 086880 A1 AR086880 A1 AR 086880A1 AR P120102045 A ARP120102045 A AR P120102045A AR P120102045 A ARP120102045 A AR P120102045A AR 086880 A1 AR086880 A1 AR 086880A1
- Authority
- AR
- Argentina
- Prior art keywords
- disorders
- halogen
- trifluoromethyl
- lower alkyl
- pyridin
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D265/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom and one oxygen atom as the only ring hetero atoms
- C07D265/28—1,4-Oxazines; Hydrogenated 1,4-oxazines
- C07D265/30—1,4-Oxazines; Hydrogenated 1,4-oxazines not condensed with other rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Diabetes (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Psychiatry (AREA)
- Pain & Pain Management (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Addiction (AREA)
- Emergency Medicine (AREA)
- Hospice & Palliative Care (AREA)
- Endocrinology (AREA)
- Anesthesiology (AREA)
- Psychology (AREA)
- Child & Adolescent Psychology (AREA)
- Nutrition Science (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Abstract
La presente se refiere a compuestos de la fórmula (1) en la que: R1 es hidrógeno, halógeno, ciano, alquilo inferior, alquilo inferior sustituido por halógeno, alcoxi inferior, alcoxi inferior sustituido por halógeno o C(O)NH2, o es fenilo opcionalmente sustituido por halógeno, ciano o alcoxi inferior sustituido por halógeno, o es 2,2-difluorobenzo[d][1,3]dioxol-5-ilo, o es 6-(trifluorometil)-pirazin-2-ilo o 5-(trifluorometil)-pirazin-2-ilo o es 6-(trifluorometil)-pirimidin-4-ilo, o es 6-(trifluorometil)-piridin-3-ilo, o es 5-cianopirazin-2-ilo o es 2-(trifluorometil)pirimidin-4-ilo; n es el número 1 ó 2; R2 es halógeno, alquilo inferior o ciano y R3 es hidrógeno, o R2 es hidrógeno y R3 es halógeno, alquilo inferior o ciano; X es un enlace, -NR’-, -CH2NH- o -CHR’-; R’ es hidrógeno o alquilo inferior; Z es un enlace, -CH2- u -O-; Ar es fenilo o es heteroarilo elegido entre el grupo formado por 1H-indazol-3-ilo, piridin-2-ilo, piridin-3-ilo, piridin-4-ilo, pirimidin-5-ilo, 1H-pirazol-3-ilo, 1H-pirazol-4-ilo y 1H-pirazol-5-ilo; o una sal de adición de ácido farmacéuticamente apropiada de los mismos; que pueden utilizarse para el tratamiento de la depresión, los trastornos de ansiedad, el trastorno bipolar, el trastorno de hiperactividad con déficit de atención (ADHD), los trastornos relacionados con el estrés, los trastornos psicóticos, la esquizofrenia, las enfermedades neurológicas, la enfermedad de Parkinson, los trastornos neurodegenerativos, la enfermedad de Alzheimer, la epilepsia, la migraña, la hipertensión, el abuso de sustancias, los trastornos metabólicos, los trastornos de ingestión de comida, la diabetes, las complicaciones diabéticas, la obesidad, la dislipidemia, los trastornos de consumo y asimilación de energía, los trastornos y mal función de la homeostasis de la temperatura corporal, los trastornos del sueño y del ritmo circadiano y los trastornos cardiovasculares.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP11169441 | 2011-06-10 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR086880A1 true AR086880A1 (es) | 2014-01-29 |
Family
ID=46298391
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP120102045A AR086880A1 (es) | 2011-06-10 | 2012-06-08 | Derivados de morfolin-benzamidas sustituidas, composiciones farmaceuticas que los contienen y uso de las mismas para tratar enfermedades asociadas fundamentalmente al sistema nervioso central |
Country Status (33)
| Country | Link |
|---|---|
| US (1) | US9029370B2 (es) |
| EP (1) | EP2718271B1 (es) |
| JP (1) | JP5788087B2 (es) |
| KR (1) | KR101574906B1 (es) |
| CN (1) | CN103596937B (es) |
| AR (1) | AR086880A1 (es) |
| AU (1) | AU2012266462B2 (es) |
| BR (1) | BR112013030698B1 (es) |
| CA (1) | CA2834675C (es) |
| CL (1) | CL2013003485A1 (es) |
| CO (1) | CO6811866A2 (es) |
| CY (1) | CY1116769T1 (es) |
| DK (1) | DK2718271T3 (es) |
| EA (1) | EA022376B1 (es) |
| EC (1) | ECSP13013073A (es) |
| ES (1) | ES2546529T3 (es) |
| HK (1) | HK1192562A1 (es) |
| HR (1) | HRP20151201T1 (es) |
| IL (1) | IL229335A (es) |
| MA (1) | MA35194B1 (es) |
| MX (1) | MX354410B (es) |
| MY (1) | MY162461A (es) |
| PE (1) | PE20140968A1 (es) |
| PH (1) | PH12013502263A1 (es) |
| PL (1) | PL2718271T3 (es) |
| PT (1) | PT2718271E (es) |
| RS (1) | RS54415B1 (es) |
| SG (1) | SG194840A1 (es) |
| SI (1) | SI2718271T1 (es) |
| TW (1) | TWI445701B (es) |
| UA (1) | UA110388C2 (es) |
| WO (1) | WO2012168265A1 (es) |
| ZA (1) | ZA201308401B (es) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9073911B2 (en) | 2011-06-09 | 2015-07-07 | Hoffmann-La Roche Inc. | Pyrazole derivatives |
| MX354815B (es) * | 2012-01-12 | 2018-03-22 | Hoffmann La Roche | Derivados heterociclicos como receptores asociados con las aminas traza (taars). |
| PE20150735A1 (es) * | 2012-09-14 | 2015-05-17 | Hoffmann La Roche | Derivados de pirazol-carboxamida como moduladores de taar para uso en el tratamiento de numerosos desordenes, tales como depresion, diabetes y enfermedad de parkinson |
| ES2605632T3 (es) * | 2012-09-17 | 2017-03-15 | F. Hoffmann-La Roche Ag | Derivados triazol carboxamida |
| WO2014072257A1 (en) * | 2012-11-07 | 2014-05-15 | F. Hoffmann-La Roche Ag | Pyrazine derivatives |
| WO2015165085A1 (en) * | 2014-04-30 | 2015-11-05 | F.Hoffmann-La Roche Ag | Morpholin-pyridine derivatives |
| RU2016149984A (ru) * | 2014-05-28 | 2018-07-02 | Ф. Хоффманн-Ля Рош Аг | Производные 5-окса-2-азабицикло[2.2.2]октан-4-ила и 5-окса-2-азабицикло[2.2.1]гептан-4-ила в качестве модуляторов taar1 |
| CN104478798B (zh) * | 2014-12-18 | 2017-01-18 | 武汉华纳联合药业有限公司 | N‑氨基烷基磺酰基‑3‑吡啶甲酰胺衍生物及其在制备治疗心脑血管病药物中的应用 |
| MX377836B (es) * | 2016-03-17 | 2025-03-11 | F Hoffmann La Roche Ag | Derivado de 5-etil-4-metil-pirazol-3-carboxamida teniendo actividad como agonista de receptor asociado con aminas trazas (taar). |
| CA3146830A1 (en) * | 2019-07-11 | 2021-01-14 | F. Hoffmann-La Roche Ag | Process for the preparation of substituted pyrazole derivatives |
| AU2021225921A1 (en) * | 2020-02-28 | 2022-09-22 | Board Of Regents, The University Of Texas System | Inhibitors of Receptor Interacting Protein Kinase I for the treatment of disease |
| TW202440563A (zh) * | 2022-11-28 | 2024-10-16 | 美商住友製藥美國公司 | 2-苯基嗎啉與2-苯基(硫代)嗎啉化合物及其用途 |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB9425211D0 (en) | 1994-12-14 | 1995-02-15 | Ucb Sa | Substituted 1H-imidazoles |
| GB9520150D0 (en) * | 1995-10-03 | 1995-12-06 | Orion Yhtymae Oy | New imidazole derivatives |
| SK8542000A3 (en) | 1997-12-04 | 2001-03-12 | Allergan Sales Inc | Substituted imidazole derivatives having agonist-like activity at alpha 2b or 2b/2c adrenergic receptors |
| US6841684B2 (en) * | 1997-12-04 | 2005-01-11 | Allergan, Inc. | Imidiazoles having reduced side effects |
| AR050865A1 (es) * | 2004-09-09 | 2006-11-29 | Sanofi Aventis | Derivados de 2- morfolino-4-pirimidona |
| WO2008026046A1 (en) | 2006-08-30 | 2008-03-06 | Pfizer Products Inc. | Morpholine d3 dopamine antagonists |
| CL2007003874A1 (es) | 2007-01-03 | 2008-05-16 | Boehringer Ingelheim Int | Compuestos derivados de benzamida; composicion farmaceutica que comprende a dichos compuestos; y su uso para tratar enfermedades cardiovasculares, hipertension, aterosclerosis, reestenosis, ictus, insuficiencia cardiaca, lesion isquemica, hipertensio |
| JP2010517969A (ja) * | 2007-02-02 | 2010-05-27 | ノバルティス アーゲー | クロメンｓ１ｐ１受容体アンタゴニスト |
| RU2460725C2 (ru) | 2007-02-15 | 2012-09-10 | Ф. Хоффманн-Ля Рош Аг | Новые 2-аминооксазолины в качестве лигандов taar1 |
| CA2695071A1 (en) | 2007-08-02 | 2009-02-05 | F. Hoffmann-La Roche Ag | The use of benzamide derivatives for the treatment of cns disorders |
| UY32858A (es) | 2009-08-31 | 2011-03-31 | Abbott Healthcare Products Bv | Derivados de (tio)morfolina como moduladores de sip |
| PT2473049T (pt) | 2009-09-04 | 2019-03-04 | Sunesis Pharmaceuticals Inc | Inibidores de tirosina quinase de bruton |
| US8354441B2 (en) | 2009-11-11 | 2013-01-15 | Hoffmann-La Roche Inc. | Oxazoline derivatives |
| US9452980B2 (en) * | 2009-12-22 | 2016-09-27 | Hoffmann-La Roche Inc. | Substituted benzamides |
| US9132136B2 (en) * | 2010-08-02 | 2015-09-15 | Hoffmann-La Roche Inc. | Pharmaceutical combination |
| US9073911B2 (en) | 2011-06-09 | 2015-07-07 | Hoffmann-La Roche Inc. | Pyrazole derivatives |
-
2012
- 2012-06-01 US US13/485,993 patent/US9029370B2/en active Active
- 2012-06-06 MY MYPI2013003963A patent/MY162461A/en unknown
- 2012-06-06 SI SI201230320T patent/SI2718271T1/sl unknown
- 2012-06-06 PE PE2013002778A patent/PE20140968A1/es active IP Right Grant
- 2012-06-06 UA UAA201400121A patent/UA110388C2/ru unknown
- 2012-06-06 SG SG2013082656A patent/SG194840A1/en unknown
- 2012-06-06 EA EA201391815A patent/EA022376B1/ru not_active IP Right Cessation
- 2012-06-06 JP JP2014514044A patent/JP5788087B2/ja active Active
- 2012-06-06 EP EP12727633.5A patent/EP2718271B1/en active Active
- 2012-06-06 PH PH1/2013/502263A patent/PH12013502263A1/en unknown
- 2012-06-06 DK DK12727633.5T patent/DK2718271T3/en active
- 2012-06-06 RS RS20150747A patent/RS54415B1/en unknown
- 2012-06-06 MX MX2013014371A patent/MX354410B/es active IP Right Grant
- 2012-06-06 ES ES12727633.5T patent/ES2546529T3/es active Active
- 2012-06-06 WO PCT/EP2012/060637 patent/WO2012168265A1/en active Application Filing
- 2012-06-06 PT PT127276335T patent/PT2718271E/pt unknown
- 2012-06-06 AU AU2012266462A patent/AU2012266462B2/en not_active Ceased
- 2012-06-06 CN CN201280028534.4A patent/CN103596937B/zh active Active
- 2012-06-06 PL PL12727633T patent/PL2718271T3/pl unknown
- 2012-06-06 BR BR112013030698-0A patent/BR112013030698B1/pt active IP Right Grant
- 2012-06-06 KR KR1020147000701A patent/KR101574906B1/ko active Active
- 2012-06-06 CA CA2834675A patent/CA2834675C/en active Active
- 2012-06-07 TW TW101120551A patent/TWI445701B/zh active
- 2012-06-08 AR ARP120102045A patent/AR086880A1/es unknown
-
2013
- 2013-11-07 IL IL229335A patent/IL229335A/en active IP Right Grant
- 2013-11-07 ZA ZA2013/08401A patent/ZA201308401B/en unknown
- 2013-11-29 CO CO13281375A patent/CO6811866A2/es active IP Right Grant
- 2013-12-05 CL CL2013003485A patent/CL2013003485A1/es unknown
- 2013-12-10 EC ECSP13013073 patent/ECSP13013073A/es unknown
- 2013-12-18 MA MA36585A patent/MA35194B1/fr unknown
-
2014
- 2014-06-20 HK HK14105919.1A patent/HK1192562A1/zh not_active IP Right Cessation
-
2015
- 2015-10-06 CY CY20151100894T patent/CY1116769T1/el unknown
- 2015-11-09 HR HRP20151201TT patent/HRP20151201T1/hr unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR086880A1 (es) | Derivados de morfolin-benzamidas sustituidas, composiciones farmaceuticas que los contienen y uso de las mismas para tratar enfermedades asociadas fundamentalmente al sistema nervioso central | |
| AR085478A1 (es) | Derivados heterociclicos de amina | |
| AR088741A1 (es) | Derivados de pirazol | |
| CO6321133A2 (es) | Nuevas 2-aminooxazolinas como ligandos taar1 para trastornos cns | |
| AR067772A1 (es) | Derivados piperazinicos de nicotinamida, medicamentos que los contienen, proceso para prepararlos y usos de los mismos para el tratamiento de trastornos asociados al sistema nervioso, cardiovascular y/o trastornos metabolicos. | |
| AR063326A1 (es) | Aminometil-2-imidazoles, medicamentos que los contienen, metodo de preparacion, y usos para el tratamiento de trastornos asociados al sistema nervioso central | |
| HRP20171981T1 (hr) | Derivati pirazolkarboksamida kao taar modulatora za uporabu u liječenju nekoliko poremećaja poput depresije, dijabetesa i parkinsonove bolesti | |
| CO6331336A2 (es) | Derivados de 4,5-dihidro-oxazol-2-ilo | |
| AR089691A1 (es) | Derivados heterociclicos | |
| MX378486B (es) | Derivados de 2-oxa-5-azabiciclo[2.2.1]heptan-3-ilo. | |
| MX2016016488A (es) | Derivados de azetidina sustituidos como ligandos de receptores asociados a aminas en trazas (taar). | |
| MX2015001108A (es) | Derivados de triazol carboxamida. | |
| RU2016146560A (ru) | Производные морфолин-пиридина | |
| BR112013010558A2 (pt) | derivados de di-hidro-oxazol-2-amina | |
| SI3149002T1 (en) | 5-Oxa-2-azabicyclo (2.2.2) octan-4-yl and 5-oxa-2-azabicyclo (2.2.1) heptan-4-yl derivatives as TAAR1 receptor modulators | |
| AR076979A1 (es) | 2- aminooxazolinas como ligandos de taar1 | |
| RU2017106928A (ru) | Замещенные производные пиразино[2,1-а]изохинолина для лечения заболеваний цнс | |
| TH146321A (th) | อนุพันธ์ของเบนซาไมด์ที่ถูกแทนที่ |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FB | Suspension of granting procedure |